Save the date for the FSP's Summer Pathology Conference on July 10-12, 2026 in Palm Beach, Florida at the Eau Palm Beach Resort & Spa. We hope to see you there!

Patti L. Ellis, BSN, RN, CPHRM, FASHRM
Senior Patient Safety Risk Manager
The Doctors Company
Topic: Prevention of Medical Errors Course

Cristina Magi-Galluzzi, MD, PhD, FCAP
Professor & Chair of Pathology
The Robert and Ruth Anderson Endowed Chair in Pathology in the Heersink School of Medicine
Section Head, Genitourinary Pathology
Director, Genitourinary Pathology Fellowship Program
Senior Scientist, O’Neal Comprehensive Cancer Center
UAB | The University of Alabama at Birmingham
Birmingham, AL
Topic: GU Pathology

Sanjay Mukhopadhyay, MD
Staff Pathologist
Cleveland Clinic
Cleveland, OH
Topic: Thoracic Pathology

Miguel Reyes-Múgica, MD
Clinical Professor
Chief of Pediatric & Perinatal Pathology Division
Program Director, Pediatric & Perinatal Pathology Fellowship
University of Miami Miller School of Medicine
Miami, FL
Topic: Placenta Pathology

Humberto Trejo Bittar, MD
Associate Member, Thoracic Pathology
Director of Autopsy Service
Department of Pathology, Moffitt Cancer Center
Tampa, FL
Topic: Thoracic Microscopy Session
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
[field_upload_1]
Coming Soon!

As targeted therapies for recurrent ovarian cancer (OC) expand, predictive biomarker testing is crucial for guiding treatment decisions. Molecular profiling is essential for identifying patients with progressive disease who are most likely to benefit from precision therapies, including with antibody–drug conjugates (ADCs). In the recurrent setting, HER2, FR-alpha, CDH6, among other markers, are key to identifying patients who may be candidates for FDA-approved or investigational ADCs via clinical trials. These advances reflect a broader shift toward personalized care in OC, with biomarker-driven therapies offering the potential for greater efficacy and improved patient outcomes.
In this series of live workshops from PeerView, leading pathology experts will explore the growing role of biomarker-driven treatment selection in OC and provide practical guidance on working closely with the multidisciplinary team to guide therapeutic decisions based on molecular findings. Stay current with the latest scientific developments, best practices, and clinical trial evidence, and take advantage of the opportunity to ask the experts your questions! Bring this meeting to your institution to learn how you can translate biomarker testing results into personalized precision treatments!
This CME/CC/AAPA activity is provided by PVI, PeerView Institute for Medical Education. PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported through independent educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Merck & Co., Inc., Rahway, NJ, USA.

The 2026 Summer Pathology Conference will take place at the Eau Palm Beach Resort & Spa located at 100 S Ocean Blvd, Manalapan, FL 33462.
Eau Palm Beach Resort & Spa is a Forbes Five-Star, AAA Five-Diamond oceanfront retreat set on seven acres of private beach in Palm Beach. Designed by Jonathan Adler, its 309 rooms and suites feature bright, modern décor and private balconies with sweeping Atlantic views. Highlights include the award-winning 42,000-square-foot Eau Spa, two oceanfront pools, tennis courts, water sports, and curated kids’ programs. Guests can enjoy diverse dining options—from upscale seafood and Italian to casual oceanfront fare—and unwind in an atmosphere that blends Palm Beach glamour with playful sophistication.
FSP attendees enjoy a discounted rate of $379/night. To book your room you must first be registered for the conference. Upon registering you will receive a confirmation email with a booking link. The discounted room rate is available until June 19, 2026 or until the group rate is sold out.




More Information Coming Soon!
Please join us at the FSP's Summer Pathology Conference taking place on July 10-12, 2026 at the Eau Palm Beach Resort & Spa in Palm Beach, FL. Exhibitors will connect with over 150 pathologists during the conference as well as engage in over 12 hours of face to face time with attendees.
hide
hide
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
APS Medical Billing is a premier billing firm that provides expert billing and practice management solutions to pathology and laboratory practices nationwide. APS’ clients range in size from a single-physician practice to large, multi-site academic departments, reference and independent labs. The scope of our billing services and proven strategies allow APS to effectively bill for professional, technical and global components of anatomic and clinical pathology services.
Biocartis is a molecular diagnostics company focused on rapid, decentralized testing. Its flagship platform, Idylla™, enables fully automated, sample-to-result analysis for oncology and infectious disease applications. Designed for ease of use in clinical labs, Biocartis delivers fast, accurate biomarker results without the need for extensive infrastructure. The company partners with pharmaceutical and diagnostic firms to expand its test menu, supporting personalized medicine and timely treatment decisions worldwide.
Blueprint Medicines, a Sanofi company, is a global biopharmaceutical company that invents life-changing medicines. We seek to improve and extend patients' lives by solving important medical problems, with a focus on allergy/inflammation and oncology/hematology.
Caris Life Sciences® is a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition.?Through comprehensive molecular profiling (DNA, RNA and proteins) and the application of AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease. This provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.
Cleveland Clinic Laboratories, led by a team of expert physicians and staff, delivers unparalleled diagnostic services through subspecialized expertise and integrated, best-practice approaches. Our team includes over 100 board-certified anatomic and clinical pathologists, alongside highly skilled medical technologists and laboratory technicians, ensuring precision in every test result and diagnosis. Offering a comprehensive range of tests from a centralized location, we maintain quick turnaround times and specimen integrity. Centralized data, accessible support, and strong collaboration between the laboratory and ordering providers streamline the diagnostic process, reducing time to diagnosis and treatment for patients worldwide.
We exist to create innovative medicines that change the standard of care. With purpose and rigor, we develop life-changing solutions for the patients of today and tomorrow. To realize high-quality therapies and cures, no detail is too small, no scientific challenge too difficult. Our heritage inspires us to rise to new challenges with continuous innovation.
Diagnexia connects pathology labs to a network of subspecialty pathologists, offering efficient primary diagnostic caseload management. We provide state-licensed, subspecialty-trained pathologists, seamless case submission, and timely reporting. Whether you have a digital scanner or not, we ensure comprehensive reports and data security.
Gestalt transforms pathology through intelligent, vendor-neutral digital solutions designed for modern laboratories. Because every day matters, we help organizations modernize workflow, scale operations, and integrate AI with confidence. Our PathFlow® platform supports Anatomic Pathology, Academic, and Research environments within a configurable, interoperable digital workflow. Beyond workflow, Gestalt develops proprietary AI algorithms, delivers custom AI solutions, and integrates with a growing ecosystem of diagnostic and research applications. Complemented by comprehensive IT and Cloud Services, we enable laboratories to choose the tools that fit today, evolve over time, and build sustainable, future-ready digital pathology strategies.
Precision Medicine at J&J is working to advance cancer care across multiple diseases with biomarker-informed therapies in oncology.
MLabs is a full-service reference laboratory at Michigan Medicine, providing expert services and rapid turnaround times to physicians nationally and internationally. We specialize in cutting-edge molecular tests for diagnoses, therapeutic evaluations and residual disease monitoring. Our disease-specific service lines include a comprehensive array of single gene assays and next generation sequencing panels. Working with some of the world’s strongest diagnostic pathologists, scientists and geneticists at MLabs, we provide consultative services for challenging cases in all subspecialities. CLIA-certified/CAP-accredited, MLabs has 35+ years of extensive experience and offers personalized service with cost-effective and expert quality laboratory results.
Molecular thyroid diagnostics
Labcorp Oncology, a division of Labcorp, delivers comprehensive, data-driven cancer diagnostics to support precision medicine. Our portfolio includes advanced genomic profiling, liquid biopsy, and minimal residual disease (MRD) testing, enabling clinicians to make informed decisions across the continuum of care. Backed by extensive clinical expertise and a national laboratory network, Labcorp Oncology partners with pathologists and oncologists to provide timely, high-quality insights that improve patient outcomes.
MedReceivables Advisor Healthcare Inc. is a full service outsourcing medical billing company specializing in Pathology for hospital based physicians.
At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.
MilliporeSigma is a leader in innovative products in life science. Cell MarqueTM Tissue Diagnostics, part of the Sigma-Aldrich portfolio, offers extensive expertise in tissue detection. Our focus is on primary antibody development from IVD-validated products to lab-developed tests. We aim to be your partner in pathology by offering custom antibody development services, an innovative selection of purified antibodies for spatial biology, routine and special stains for histology, and so much more.
MSN Healthcare Solutions provides comprehensive and proactive billing, accounts receivable and practice management services to pathology practices nationwide. The breadth and depth of MSN’s experience and involvement in the pathology environment provides clients with confidence, trust and results. MSN provides services beyond the typical billing company, such as providing detailed coding feedback and being approved by CMS as a Qualified Clinical Data Registry (QCDR) for MIPS measure creation, submission and reporting.
Roche provides innovative diagnostic solutions to increase productivity in pathology labs and to help healthcare providers make faster, more confident decisions. Our portfolio includes automated slide staining and state of the art sample tracking, a broad menu of diagnostic assays, and digital pathology solutions. We partner with our customers to improve workflow efficiency, deliver enhanced medical value, and ensure safety for both the user and the patient.
Sonic Healthcare
Next Generation Sequencing for Clinical Oncology Molecular Testing
Afirma® Genomic Sequencing Classifier is a comprehensive solution to help personalize diagnosis and treatment for patients with thyroid nodules.
hide
More Information Coming Soon!
hide
hide
hide
hide
hide
hide
FSP Member Login